Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott Becomes First Anchor Sponsor For American Diabetes Association Health Equity Now Initiative

Executive Summary

Abbott will commit $5m to support the ADA’s efforts to bring diabetes technologies and education to underserved diabetes populations.

You may also be interested in...



Abbott Wants To Expand Clinical Trial Access By Diversifying Investigator Community

The company’s plan to reduce barriers to clinical trial participation for underrepresented groups includes the creation of nearly 300 new scholarships at medical schools of historically black colleges and universities and minority nursing associations.

ADA 2021: Encouraging Trial Data On CGMs, Insulin Pens, Digital Solutions, And More

The American Diabetes Association held its 81st Scientific Sessions from 25-29 June, where a range of presentations covering clinical trials of continuous glucose monitors, insulin-delivery systems and remote monitoring technologies were given.

Medtronic Addresses Diabetes Care Disparities With New Equity Initiatives

The company announced new research investments and partnerships with the American Diabetes Association and the T1D Exchange to address racial disparities in treatment of diabetes.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT143098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel